Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | GALK1 | P51570 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201517 | 0.86 | ELANE (0.40) | FBP1NPC1RAB9AMAPTMEN1 | |
| SCHEMBL28611707 | 0.81 | PIK3CA (0.49) | FBP1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL7899328 | 0.80 | RAB9A (0.64) | FBP1NPC1RAB9AMAPTKMT2A | |
| SCHEMBL13257845 | 0.79 | PIK3CA (0.51) | FBP1NPC1RAB9AMAPTMEN1 | |
| SCHEMBL14099928 | 0.79 | IL6 (0.58) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL21154027 | 0.79 | LMNA (0.56) | FBP1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL7891273 | 0.77 | NPC1 (0.42) | FBP1NPC1RAB9AMAPTELANE | |
| SCHEMBL28837682 | 0.77 | NPC1 (0.66) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23033253 | 0.76 | MAPT (0.54) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL13754403 | 0.76 | IL6 (0.56) | NPC1RAB9AMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115485281-B | FGFR and mutation inhibitor thereof, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4169922-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-115485281-A | FGFR and mutation inhibitor thereof, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
| US-20160287596-A1 | Benzoxazole Kinase Inhibitors and Methods of Use | FAETH THERAPEUTICS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-9345706-B2 | Benzoxazole kinase inhibitors and methods of use | INTELLIKINE, LLC (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150306105-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | FAETH THERAPEUTICS, INC. | 2015-10-29 | — | — | US | disclosed |
| US-20140128599-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140030256-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-8476282-B2 | Benzoxazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476431-B2 | Benzoxazole kinase inhibitors and methods of use | Itellikine LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8450329-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-8450480-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306105-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | BMX, MTOR, PDPK1 | FBP1 1192/4885NPC1 1622/4885RAB9A 2472/4885 |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | FGFR3, FGFR1, FGFR4 | FBP1 1903/4885NPC1 2173/4885RAB9A 3048/4885 |
| US-20140128599-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | BMX, MTOR, PDPK1 | FBP1 1192/4885NPC1 1622/4885RAB9A 2472/4885 |
| US-20160287596-A1 | Benzoxazole Kinase Inhibitors and Methods of Use | BMX, MTOR, PDPK1 | FBP1 1192/4885NPC1 1622/4885RAB9A 2472/4885 |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | FBP1 1192/4885NPC1 1622/4885RAB9A 2472/4885 |
| US-20140030256-A1 | BENZOXAZOLE KINASE INHIBITORS AND METHODS OF USE | BMX, MTOR, PDPK1 | FBP1 1192/4885NPC1 1622/4885RAB9A 2472/4885 |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | FBP1 1192/4885NPC1 1622/4885RAB9A 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.